

## Special Issue

# Recent Advances in Liquid Biopsy Biomarkers of Cancer

### Message from the Guest Editor

We invite you to contribute to this Special Issue, titled "Recent Advances in Liquid Biopsy Biomarkers of Cancer". It will focus not only on the discovery of novel cancer biomarkers, such as genetic, epigenetic, proteomic, circulating microbial DNA, fragmentome, and metabolic markers in liquid biopsy for clinical applications, but also on analytical assay development, validation, and reference material development for these biomarker measurements. Additionally, we will explore emerging tools and advanced computational methodologies for detecting cancer biomarkers in liquid biopsy. For this Special Issue, we welcome original research articles, reviews, and perspective or opinion pieces discussing challenges and future directions in the field. We look forward to receiving your contributions.

### Guest Editor

Dr. Hua-Jun He

National Institute of Standards and Technology, Gaithersburg, MD, USA

### Deadline for manuscript submissions

15 January 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/233087](https://mdpi.com/si/233087)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)